Rebecca A. Previs
机构: Director of Medical Affairs, Oncology, Labcorp; Adjunct Assistant Professor, Duke University Medical
每年引用次数
引用次数
引用: 3,466
H-指数: 30
I10-指数 : 55
出版物: 273
Turning ΡroΜisΕ into practice: Predicting response in medically managed endometrial cancers via molecular classification
A.M. Puechl , D. Spinosa , A. Berchuck , K.E. Drury
Gynecologic Oncology 159 17
2020
Pembrolizumab window study: Illuminating the immunologic landscape in gynecologic cancers
S. Gaillard , G. Broadwater , W.S. Andrews , M.D. Starr
Gynecologic Oncology 159 41
2020
CaMKK2-can: A dance between CaMKK2 and Rb in high-grade serous ovarian cancer patients with therapeutic potential
C.Y. Chang , R.S. Whitaker , K.C. Strickland , A. Berchuck
Gynecologic Oncology 154 54
2019
Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer
A.A. Secord , R.A. Previs , B. Pothuri , K.C. Strickland
Gynecologic Oncology 154 248
2019
Selective activation of Notch3 in high-grade serous ovarian cancer
W. Hu , T. Liu , C. Ivan , J. Huang
Gynecologic Oncology 133 115
2014
Taking it up a Notch: Implications for outcomes in endometrial cancer
R.A. Previs , C. Ivan , H.J. Dalton , A.N. Davis
Gynecologic Oncology 133 132 -133
2014
Homologous recombination deficiency in endometrioid uterine cancer: An unrecognized phenomenon
J.M. Hansen , K.A. Baggerly , Y. Wang , S. Wu
Gynecologic Oncology 137 21
2
2015
Molecular predictors of response to EphA2 targeted therapy in uterine cancer
A.K. Sood , J. Huang , W. Hu , R.A. Previs
Gynecologic Oncology 137 59
2015
Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?
K.C. Fuh , A.A. Secord , K.S. Bevis , W.K. Huh
Gynecologic Oncology 137 56
1
2015
The FAK of uterine cancer: PTEN expression predicts response of uterine cancer to focal adhesion kinase inhibition
R.A. Previs , D. Thanapprapasr , W. Hu , R. Rupaimoole
Gynecologic Oncology 137 59
2015
Role of increased n-acetylaspartate levels in epithelial ovarian cancer
B. Zand , R.A. Previs , N.M. Zacharias , R. Rupaimoole
Gynecologic Oncology 137 68
2015
Fuel for the fire: connecting genomics with metabolomics in ovarian cancer
R.A. Previs , T.J. Moss , B. Zand , R. Rupaimoole
Gynecologic Oncology 137 67
2015
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
R.A. Previs , K.S. Bevis , W. Huh , T. Tillmanns
Gynecologic Oncology 132 ( 3) 531 -536
15
2014
Wound healing gone awry: Role for platelets in tumor growth after antiangiogenic therapy
J.N. Bottsford-Miller , M. Taylor , H.J. Dalton , R.L. Stone
Gynecologic Oncology 133 19
1
2014
More is not always better: Thrombocytosis contributes to impaired chemotherapy response in ovarian cancer
J.N. Bottsford-Miller , M. Taylor , H.J. Dalton , R.L. Stone
Gynecologic Oncology 133 20 -21
2014
A dose a day keeps the cancer away: Metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer
A.N. Davis , Y.G. Lin , R.A. Previs , H.J. Dalton
Gynecologic Oncology 133 71
2014
Not your mother's bisphosphonate: Targeting angiogenesis in ovarian cancer
H.J. Dalton , N.M. Reusser , A. Zien , R.A. Previs
Gynecologic Oncology 133 42
2014
Hitting the right mark: Nonoverlapping Notch and PI3K alterations in ovarian cancer
A.N. Davis , C. Ivan , R.A. Previs , H.J. Dalton
Gynecologic Oncology 133 96
2014
Two to tango: Biological activity and companion predictive markers for a novel dual AKT and P70S6K inhibitor in ovarian and uterine malignancies
R.A. Previs , G.N. Armaiz-Pena , C. Ivan , H.J. Dalton
Gynecologic Oncology 141 5
2016
PTEN loss predicts response to Notch pathway inhibition in endometrial cancer
J.M. Hansen , R.A. Previs , Y.A. Lyons , Y. Wang
Gynecologic Oncology 141 5 -6
2016